Welcome to today's podcast, where we discuss a concerning trend regarding new weight-loss drugs, particularly semaglutide, the active ingredient in Ozempic and Wegovy. A recent study led by the CDC reveals that nearly 25,000 Americans ended up in the emergency room due to complications from these medications between 2022 and 2023.

According to the research published in the Annals of Internal Medicine, gastrointestinal issues were the most common reason for these ER visits, making up almost 70% of the cases. “Clinicians could counsel patients when initiating semaglutide about the potential for severe gastrointestinal adverse effects,” the authors highlighted. They also noted that around 9% of the visits were due to medication errors, indicating the need for better education for patients on proper usage.

Though GLP-1 drugs like semaglutide have been celebrated for their effectiveness in weight loss and managing type 2 diabetes, their increased use has brought about significant risks. With over 82% of these visits occurring in 2023, researchers emphasize the importance of doctors preparing patients for potential side effects and managing their overall treatment more effectively.

As the popularity of these drugs grows, navigating their benefits and risks is crucial. Stay informed and consult your healthcare provider if you're considering these medications. Thanks for tuning in!
Link to Article